$0.810250
-0.02-2.81%
At Close: -
$0.833300
0.022.84%
After Hours: Jul 3, 6:26 AM EDT
15 minutes delayed
Achilles Therapeutics
ACHLNASDAQ
Latest news for Achilles Therapeutics (NASDAQ:ACHL) Stock
Achilles Therapeutics Stock (NASDAQ: ACHL)
Categories: All
Wednesday, May 22, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
- Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
- Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Achilles Therapeutics shares are trading lowe...
- Achilles Therapeutics Q4 EPS $(0.46) May Not ...
- Achilles Therapeutics Provides Interim Phase ...
Monday, December 18, 2023
Thursday, December 14, 2023
Monday, November 13, 2023
Friday, September 22, 2023
Thursday, September 07, 2023
Monday, August 07, 2023
Friday, August 04, 2023
Thursday, May 11, 2023
Wednesday, May 10, 2023
Tuesday, April 25, 2023
Friday, January 13, 2023
Friday, January 06, 2023
Thursday, December 15, 2022
Thursday, December 08, 2022
Wednesday, December 07, 2022
Tuesday, December 06, 2022
Friday, December 02, 2022
Tuesday, November 22, 2022
Wednesday, November 09, 2022
Tuesday, November 08, 2022
Tuesday, August 09, 2022
Monday, August 08, 2022
Monday, August 01, 2022
Tuesday, July 19, 2022
Monday, July 18, 2022
Monday, June 27, 2022
Monday, May 23, 2022
Tuesday, May 10, 2022
Monday, May 09, 2022
- Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC
- Achilles Therapeutics Doses First Patient With Higher-Dose cNeT In Phase I/IIa CHIRON Trial In Advanced NSCLC And Initiates Enrollment In Cohort B Of The THETIS Trial (cNeT + PD-1 checkpoint inhibitor) In Metastatic Malignant Melanoma